OFIX
ORTHOFIX MED (OFIX)
NASDAQ
$9.72+$0.005 (+0.05%)
Price as of Jun 03, 2026 4:38 PM EDT
  • $374.7M
    Market Cap
  • -11.97%
    1-Year Change
  • Medical Devices
    Industry

Key Performance

More
  • Earnings Score: 40
  • Momentum Score: 20
  • True Yield: N/A
  • Financial Health Score: 55
TradeSmith Loading

Latest Research & News

Orthobiologics Market to Surpass USD 9 Billion by 2031 Amid Rising Osteoarthritis Cases and Advancements in Regenerative Therapies, Says Mordor Intelligence

The global orthobiologics market is projected to grow from USD 6.68 billion in 2025 to USD 9.52 billion by 2031, with a CAGR of 6.17%. Growth is driven by rising osteoarthritis cases, sports-related injuries, and advancements in regenerative therapies including stem cell therapy and platelet-rich plasma treatments. North America leads the market while Asia-Pacific is the fastest-growing region.

03/12/2026, 3:45 AM • GlobeNewswire

Orthofix (OFIX) Q2 Revenue Rises 2%

Orthofix Medical reported Q2 2025 financial results, beating earnings estimates with $203.1 million in revenue, representing 2.3% year-over-year growth. The company saw segment gains in Bone Growth Therapies and Orthopedics, with positive free cash flow and continued new product execution.

08/05/2025, 10:16 PM • The Motley Fool

Peers

Statistics

More
Day Range
$9.20
$9.75
$9.71
1-Year Range
$9.27
$16.23
$9.71
Latest Close$9.71
Change
+$0.44 (+4.53%)
Volume529,170
Market Cap$374.7M
Shares Outstanding40.4M
P/E (TTM)-6.40
Diluted EPS (TTM)-$1.45
Enterprise Value$475.8M

Information as of 06/02/2026

Company Profile

ORTHOFIX MEDICAL INC
ORTHOFIX MEDICAL INC
https://orthofix.com
$374.7M
Market Cap
-$57.8M
Net Income
Sector: Healthcare
Industry: Medical Devices
3451 Plano Parkway, Lewisville, TX, United States, 75056
214 937 2000

Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graft substitutes, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers in various forms with supporting graft delivery solutions to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and 7D FLASH Navigation System, a navigation platform for spinal and cranial procedures. The Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market, including deformity correction, limb lengthening, complex fracture management, and limb preservation. This segment also designs, develops, and markets external and internal fixation limb reconstruction products that are coupled with enabling digital technologies to support the entire patient care continuum. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, healthcare providers, ambulatory surgery centers, and out-patient hospitals. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.

Key Executives

  • Massimo Calafiore
  • Max Reinhardt
  • Lucas S. Vitale
  • J. Andres Cedron
  • Patrick Fisher

Current Ownership Distribution

  • Institutions553.2M (81.39%)
  • Mutual Funds114.1M (16.79%)
  • Insiders12.4M (1.82%)
  • Other0 (0.00%)